RENATA PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 680.5 BDT | -2.72% |
|
-9.74% | -44.13% |
| Apr. 29 | Renata PLC Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
| Feb. 13 | Renata Limited will Change its Name to Renata PLC | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 36.96B 315M | Sales 2025 * | 42.31B 360M | Capitalization | 80.23B 683M |
|---|---|---|---|---|---|
| Net income 2024 * | 4.07B 34.65M | Net income 2025 * | 5.25B 44.73M | EV / Sales 2024 * | 2.17 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.9 x |
| P/E ratio 2024 * |
19.7
x | P/E ratio 2025 * |
15.3
x | Employees | 7,119 |
| Yield 2024 * |
0.76% | Yield 2025 * |
0.99% | Free-Float | 15.16% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.37% | ||
| 1 week | -7.22% | ||
| Current month | -9.00% | ||
| 1 month | -12.61% | ||
| 3 months | -28.47% | ||
| 6 months | -42.57% | ||
| Current year | -42.57% |
1 week
695.50
759.10
1 month
695.50800.40
Current year
695.501 217.90
1 year
695.501 217.90
3 years
695.501 289.72
5 years
695.501 289.72
10 years
312.791 289.72
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 01-12-31 | |
| Director of Finance/CFO | - | - | |
| Chief Tech/Sci/R&D Officer | - | 10-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 01-12-31 | |
Sarwar Ali
CHM | Chairman | 82 | 93-12-31 |
| Director/Board Member | - | 13-08-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-18 | 680.5 | -2.72% | 9 291 |
| 24-05-16 | 699.5 | -1.37% | 10,461 |
| 24-05-15 | 709.2 | -2.60% | 12,262 |
| 24-05-14 | 728.1 | -2.14% | 11,134 |
| 24-05-13 | 744 | -0.96% | 12,569 |
End-of-day quote Dhaka S.E., May 15, 2024
More quotes
Renata PLC, formerly Renata Limited, is a Bangladesh-based pharmaceutical and animal health company. The Company is engaged in manufacturing, marketing and distribution of pharmaceutical, animal health products, oncology-based products, agro-based products, poultry products, and consumer products. The Company also engages in the business as traders, importers, exporters, commission agents of all kinds of goods and services, including pharmaceutical drugs and medicines. Its offerings include Algin Injection, Algin Syrup, Alphapress Tablet, Androcap Capsule, Becosules Capsule, Bredicon Tablet, Cabolin Tablet, Anorexon Tablet, Aquastar Growout Powder, Avinex Powder, Catophos Injection, Eggshell Tmo Powder, Ectorid Injection, Doxivet Powder, Fevenil Injection, Fluximine Injection, Cardipin Tablet, Cartilage Plus Tablet, and Diadin Injection, among others.
Sector
Pharmaceuticals
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
699.5
BDT
Average target price
1,109
BDT
Spread / Average Target
+58.54%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -42.57% | 684M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- RENATA Stock
